Related Experiment Videos
The effect of transforming growth factor-beta 2-specific phosphorothioate-anti-sense oligodeoxynucleotides in
P Jachimczak1, U Bogdahn, J Schneider
1Department of Neurology, University of Würzburg, Germany.
Abstract:
This in vitro study was aimed at restitution of transforming growth factor (TGF)-beta 2-mediated suppression of T-lymphocyte activation within malignant gliomas. In early-passage tumor cell cultures of two glioblastomas (HTZ-153 and HTZ-209) and one malignant astrocytoma classified as World Health Organization Grade III (HTZ-243), autologous peripheral blood mononuclear cells were activated by interleukin-1 alpha and interleukin-2 in vitro (lymphokine-activated killer cells) and tested for cytotoxic and proliferative activity. In expression studies (Western blot and Northern hybridization) of all three tumors, TGF-beta could be detected at the protein and messenger ribonucleic acid (mRNA) levels. A polyclonal anti-TGF-beta neutralizing antibody did not enhance lymphocyte proliferation upon stimulation with tumor targets (3H-thymidine incorporation) and slightly stimulated lymphocyte cytotoxicity against autologous target cells. Preincubation of target cells for 12 hours with TGF-beta 2-specific phosphorothioate-anti-sense oligodeoxynucleotides (S-ODN's) did, however, enhance lymphocyte proliferation up to 2.5-fold and autologous tumor cytotoxicity up to 60%, compared to controls not treated with S-ODN's. Incubation of tumor cells with TGF-beta 2-specific S-ODN's resulted in decreased TGF-beta-specific immunoreactivity in cultured glioma cells, in reduced TGF-beta 2 protein concentration (Western blot), and in a change in the expression pattern of TGF-beta 2 mRNA's. These observations may have implications for in vivo and in vitro activation of a cellular immune response against autologous malignant glioma cells.
Insights
Researchers investigated how to restore T-lymphocyte activation in malignant gliomas. Using antisense oligonucleotides targeting transforming growth factor-beta 2 (TGF-β2) enhanced immune cell activity against glioma cells.
Area of Science:
- Neuro-oncology
- Immunology
- Molecular Biology
Background:
- Malignant gliomas suppress T-lymphocyte activation.
- Transforming growth factor-beta 2 (TGF-β2) is implicated in this immunosuppression.
- Restoring anti-tumor immune responses is a therapeutic goal.
Purpose of the Study:
- To investigate the potential of targeting TGF-β2 to overcome T-lymphocyte suppression in malignant gliomas.
- To evaluate the efficacy of TGF-β2-specific antisense oligonucleotides (S-ODNs) in enhancing anti-glioma immune responses in vitro.
Main Methods:
- In vitro study using human glioblastoma and astrocytoma cell lines.
- Activation of autologous peripheral blood mononuclear cells into lymphokine-activated killer (LAK) cells.
- Assessment of LAK cell cytotoxic and proliferative activity against tumor targets.
- Treatment of tumor cells with TGF-β2-specific S-ODNs.
- Analysis of TGF-β2 expression at protein (Western blot) and mRNA (Northern hybridization) levels.
Main Results:
- TGF-β2 was detected in glioma cells at both protein and mRNA levels.
- Anti-TGF-β antibody showed minimal effects on lymphocyte activity.
- TGF-β2-specific S-ODNs significantly enhanced LAK cell proliferation (up to 2.5-fold) and cytotoxicity (up to 60%) against autologous glioma cells.
- S-ODN treatment reduced TGF-β2 expression in glioma cells.
Conclusions:
- Targeting TGF-β2 with antisense oligonucleotides can restore T-lymphocyte activation against malignant gliomas in vitro.
- This approach holds potential for developing novel immunotherapies for glioma.
- Further in vivo studies are warranted to validate these findings.